Simple SummaryPatients with hematological malignancies have an increased risk of arterial thrombosis (ATE). Data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Out of 626 AML patients, 18 (2.9%) patients developed ATE in the median time of 3 months. Our study showed that the risk of ATE was increased in AML patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30.AbstractBackground: Patients with hematological malignancies have an increased risk of arterial thrombotic events (ATEs) after diagnosis, compared to matched controls without cancer. However, data about incidence and risk factors for ATE development in patients with acute myeloid leukemia (AML) are missing. Aim: The objectives of this study were to determine the incidence of ATE in non-promyelocytic-AML patients and to define the potential risk factors for ATE development. Methods: We conducted a retrospective cohort study of adult patients with newly diagnosed AML. The primary outcome was the occurrence of confirmed ATE, defined as myocardial infarction, stroke or critical limb ischemia. Results: Out of 626 eligible AML patients, 18 (2.9%) patients developed ATE in the median time of 3 (range: 0.23–6) months. Half of these patients died due to ATE complications. Five parameters were predictors of ATE: BMI > 30 (p= 0.000, odds ratio [OR] 20.488, 95% CI: 6.581–63.780), prior history of TE (p= 0.041, OR 4.233, 95% CI: 1.329–13.486), presence of comorbidities (p= 0.027, OR 5.318, 95% CI: 1.212–23.342), presence of cardiovascular comorbidities (p< 0.0001, OR 8.0168, 95% CI: 2.948–21.800) and cytogenetic risk score (p= 0.002, OR 2.113, 95% CI: 1.092–5.007). Conclusions: Our study showed that patients with AML are at increased risk of ATE. The risk was increased in patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30.